SYNTARA LIMITED — Capital/Financing Update 2021

Apr 20, 2021

==> picture [144 x 20] intentionally omitted <==

==> picture [144 x 20] intentionally omitted <==

21 April 2021

Section 708A(5)(e) Notice

This notice is given by Pharmaxis Ltd (ACN 082 811 630) (ASX: PXS) ( Company ) under section 708A(5)(e) of the Corporations Act 2001 (Cth) ( Corporations Act ).

The Company refers to its announcement on 14 April 2021 regarding the successful completion of a share placement to raise approximately $4.4 million ( Placement ). The Company has today issued 54,586,141 fully paid ordinary shares in the Company at an issue price of $0.08 per share ( New Shares ).

The Company confirms the following:

1. The New Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act.

2. This notice is being given under section 708A(5)(e) of the Corporations Act.

3. As at the date of this notice, the Company has complied with:

   • a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

   • b) section 674 of the Corporations Act.

4. As at the date of this notice, there is no “excluded information” of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act that is required to be set out in this notice under section 708A(6)(e) of the Corporations Act.

==> picture [165 x 80] intentionally omitted <==

David McGarvey Chief Financial Officer / Company Secretary

Pharmaxis Ltd 20 Rodborough Road T 02 9454 7200 ABN 75 082 811 630 Locked Bag 5015 F 02 9451 3622 Frenchs Forest NSW 2086 www.pharmaxis.com.au Australia